Herein, we investigated the protective effects of VPA on the auditory functions of the KCNQ4 variant and analyzed the feasibility of using an HDAC inhibitor to modulate late-onset genetic HL. This evidence concerns the gene KCNQ4 and Hodgkins lymphoma.